In addition to iron status, there are multiple regulatory factors—including acute or chronic disease, inflammation, tissue hypoxia, and oxidative stress—able to regulate hepcidin expression (for review see Ganz[8]). All forms of HH described to date result from mutations in genes either involved in the regulation of hepcidin expression, or the hepcidin/ferroportin axis (Fig. 1). The identification of the genes implicated in HH has been instrumental in informing our understanding of how iron homeostasis is regulated. Conversely, our increased understanding of iron

homeostatic regulation over the past 10–12 years has improved our understanding of the pathophysiology of these different forms of iron overload. The following sections will

describe in detail the different genetic forms of iron overload, the causative genes, and how their products are involved in the regulation of iron homeostasis. The relevance DAPT concentration of the different forms of iron overload to the Asia-Pacific region will be emphasized. HH has always been thought of as a European disease because of the high frequency of the pathogenic C282Y mutation (5% allele frequency in European populations; 1000 Genomes Project [http://www.1000genomes.org]) and hence the large number of individuals homozygous for this change.[2] Conversely, the C282Y mutation has a low frequency outside of European populations; it is virtually buy Pictilisib absent in populations of Asian or Pacific Island ancestry.[9-11] The second most significant mutation in HFE, H63D, has a much higher prevalence globally (15% allele frequency in European populations; 10–15% allele frequency in South American populations; 1000 Genomes). However, it is clinically less significant because of its modest effect on the function of HFE. While homozygosity for the H63D mutation is not associated with any clinical phenotype, individuals with compound heterozygosity for both C282Y and H63D mutations may have increased iron indices.[12, 13] The H63D mutation has been identified in Asia but is less common than in Europe (2% allele

frequency in Asian Populations; 1000 Genomes Project). Despite the low frequency of these mutations in Asia, isolated cases of C282Y homozygous HH have been reported in ethnic Rucaparib molecular weight Asians, such as a Japanese woman[14] and a Turkish family.[15] Other mutations in HFE can lead to HH in the absence of homozygosity or compound heterozygosity for C282Y or H63D.[16] However, these are rarely screened due to the high frequency of C282Y and H63D. In the Asia-Pacific region, a number of cases of HH have been ascribed to rare mutations in HFE. The E277K mutation in HFE, which has a functional effect on the protein,[17] has been reported in Asian individuals and has also been associated with a HH phenotype in Portugal.[18-20] Recently, a homozygous 3 nucleotide deletion causing a single amino acid deletion (Y231del) was identified in a Japanese patient with HH.